Ã€lvar AgustÃ-

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8746799/publications.pdf

Version: 2024-02-01

431 papers	58,541 citations	1893 102 h-index	1190 228 g-index
451 all docs	451 docs citations	451 times ranked	36665 citing authors

#	Article	IF	Citations
1	A New and More Sensitive Method to Integrate the Desaturation Distance Ratio During a 6-Minute Walking Test in Chronic Respiratory Diseases: Physiological Correlates. Archivos De Bronconeumologia, 2022, 58, 188-190.	0.8	3
2	Specific miRNA Profile in Chronic Obstructive Pulmonary Disease Related to Biomass Smoke Exposure. Archivos De Bronconeumologia, 2022, 58, 177-179.	0.8	3
3	Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1105-1113.	5.7	17
4	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Preâ€"Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	5.6	72
5	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. European Respiratory Journal, 2022, 59, 2102006.	6.7	34
6	Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies. Lancet Respiratory Medicine,the, 2022, 10, 83-94.	10.7	19
7	Lung aging and senescence in health and disease. , 2022, , 61-80.		1
8	ANTES: Un aÃ±o despuÃ©s en la EPOC. Archivos De Bronconeumologia, 2022, 58, 291-294.	0.8	1
9	The 7 Cardinal Sins of COPD in Spain. Archivos De Bronconeumologia, 2022, 58, 498-503.	0.8	0
10	Severe Pulmonary Hypertension in COPD. Chest, 2022, 162, 202-212.	0.8	29
11	Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. European Respiratory Journal, 2022, 59, 2103036.	6.7	9
12	Predicting Early Hospital Readmissions in COPD Patients Using an Electronic Nose. Archivos De Bronconeumologia, 2022, 58, 663-665.	0.8	1
13	Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. Respiratory Research, 2022, 23, 37.	3.6	23
14	<scp>CT</scp> in <scp>COPD</scp>: To be or not to be. Respirology, 2022, 27, 258-259.	2.3	4
15	MÃ¡s alla del binomio EPOC-tabaco: nuevas oportunidades para la prevenciÃ³n y tratamiento precoz de la enfermedad. Medicina ClÃ±ica, 2022, 159, 33-39.	0.6	3
16	[Translated article] Histology Study of Postmortem Lung Biopsies in Patients With Covid-19 Pneumonia. Archivos De Bronconeumologia, 2022, 58, T444-T447.	0.8	0
17	Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of geneâ€"environment interactions across the lifespan. Lancet Respiratory Medicine,the, 2022, 10, 512-524.	10.7	93
18	[Translated article] The ANTES Program in COPD: First Year. Archivos De Bronconeumologia, 2022, 58, T291-T294.	0.8	0

#	Article	IF	Citations
19	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 17-24.	5.6	57
20	Beyond the COPD-tobacco binomium: New opportunities for the prevention and early treatment of the disease. Medicina ClÃ¬nica (English Edition), 2022, 159, 33-39.	0.2	0
21	Bronchial Infection and Temporal Evolution of Bronchiectasis in Patients With Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases, 2021, 72, 403-410.	5.8	33
22	Treatable Traits That Predict Health Status and Treatment Response in Airway Disease. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1255-1264.e2.	3.8	34
23	From GOLD 0 to Pre-COPD. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 414-423.	5.6	119
24	Lung DNA Methylation in Chronic Obstructive Pulmonary Disease: Relationship with Smoking Status and Airflow Limitation Severity. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 129-134.	5.6	13
25	Are women with asthma at increased risk for severe COVID-19?. Lancet Respiratory Medicine,the, 2021, 9, 125-126.	10.7	6
26	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. European Respiratory Journal, 2021, 58, 2003927.	6.7	43
27	Low birth weight as a potential risk factor for severe COVID-19 in adults. Scientific Reports, 2021, 11, 2909.	3.3	10
28	Transitioning from infancy to adulthood: a black box full of opportunities. European Respiratory Journal, 2021, 57, 2003997.	6.7	3
29	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
30	Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 682-683.	10.7	12
31	Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. Archivos De Bronconeumologia, 2021, 57, 59-61.	0.8	36
32	Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: A longâ€term observational study. Respirology, 2021, 26, 776-785.	2.3	10
33	Cellular Senescence in Lung Fibrosis. International Journal of Molecular Sciences, 2021, 22, 7012.	4.1	33
34	Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study. ERJ Open Research, 2021, 7, 00020-2021.	2.6	11
35	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. European Journal of Internal Medicine, 2021, 89, 3-9.	2.2	19
36	COVID-19 diagnostic tests: Importance of the clinical context. Medicina ClÃ¬nica (English Edition), 2021, 157, 185-190.	0.2	6

#	Article	IF	Citations
37	Pruebas diagnÃ³sticas COVID-19: importancia del contexto clÃnico. Medicina ClÃnica, 2021, 157, 185-190.	0.6	4
38	COVID-19 and COPD: lessons beyond the pandemic. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L978-L982.	2.9	7
39	Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory Medicine, 2021, 187, 106572.	2.9	29
40	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. European Respiratory Journal, 2021, 57, 2001339.	6.7	26
41	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	6.7	8
42	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. JAMA - Journal of the American Medical Association, 2021, 326, 1277.	7.4	28
43	Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD. Frontiers in Medicine, 2021, 8, 761767.	2.6	5
44	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respiratory Medicine,the, 2020, 8, 158-170.	10.7	69
45	Clinical Fingerprinting: A Way to Address the Complexity and Heterogeneity of Bronchiectasis in Practice. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 14-19.	5.6	15
46	COPD: Challenges and opportunities. Respirology, 2020, 25, 132-133.	2.3	4
47	An imported case of e-cigarette or vaping associated lung injury in Barcelona. European Respiratory Journal, 2020, 55, 1902076.	6.7	23
48	When Harry Met Sally, or When Machine Learning Met Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 263-265.	5.6	4
49	Chronic Obstructive Pulmonary Disease Pathogenesis. Clinics in Chest Medicine, 2020, 41, 307-314.	2.1	6
50	Phenotypic characterisation of early COPD: a prospective caseâ€“control study. ERJ Open Research, 2020, 6, 00047-2020.	2.6	21
51	COPD 2020: changes and challenges. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L879-L883.	2.9	66
52	Withdrawal of inhaled corticosteroids in COPD. European Respiratory Journal, 2020, 56, 2001684.	6.7	1
53	Time for a change: anticipating the diagnosis and treatment of COPD. European Respiratory Journal, 2020, 56, 2002104.	6.7	33
54	Amerindian Ancestry Influences Genetic Susceptibility to Chronic Obstructive Pulmonary Disease. Journal of Personalized Medicine, 2020, 10, 93.	2.5	7

#	Article	IF	Citations
55	Outcomes and cost of lung cancer patients treated surgically or medically in Catalunya: costâ€"benefit implications for lung cancer screening programs. European Journal of Cancer Prevention, 2020, 29, 486-492.	1.3	7
56	Smaller Left Ventricle Size at Noncontrast CT Is Associated with Lower Mortality in COPDGene Participants. Radiology, 2020, 296, 208-215.	7.3	6
57	PRDM15 Is Associated with Risk of Chronic Obstructive Pulmonary Disease in a Rural Population in Chile. Respiration, 2020, 99, 307-315.	2.6	4
58	Blood eosinophil count in the general population: typical values and potential confounders. European Respiratory Journal, 2020, 55, 1901874.	6.7	81
59	Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1078-1085.	5.6	78
60	Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respiratory Medicine,the, 2020, 8, 436-438.	10.7	314
61	Factors Associated with Low Lung Function in Different Age Bins in the General Population. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 292-296.	5.6	36
62	El programa MENTOR, los jÃ³venes y el futuro cientÃfico de la SEPAR. Archivos De Bronconeumologia, 2020, 56, 775-776.	0.8	2
63	Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity. Respiratory Research, 2020, 21, 21.	3.6	9
64	Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?. Chronic Respiratory Disease, 2019, 16, 147997311986933.	2.4	10
65	Las bronquiectasias: una enfermedad compleja y heterogÃ©nea. Archivos De Bronconeumologia, 2019, 55, 427-433.	0.8	16
66	Heart and lungs in a single breath. Respirology, 2019, 24, 937-938.	2.3	0
67	Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respiratory Research, 2019, 20, 152.	3.6	34
68	Bronchiectasis: A Complex, Heterogeneous Disease. Archivos De Bronconeumologia, 2019, 55, 427-433.	0.8	7
69	It is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 2019, 54, 1900914.	6.7	43
70	EARLY COPD: determinantes de la apariciÃ³n y progresiÃ³n de la enfermedad pulmonar obstructiva crÃ³nica en adultos jÃ³venes. Protocolo de un estudio caso-control con seguimiento. Archivos De Bronconeumologia, 2019, 55, 312-318.	0.8	8
71	Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART. PLoS ONE, 2019, 14, e0224510.	2.5	6
72	Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2019, 381, 1248-1256.	27.0	324

#	Article	IF	Citations
73	The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2019, 55, 93-99.	0.8	5
74	Heterogeneidad y complejidad del sÃndrome bronquiectasias: un reto pendiente. Archivos De Bronconeumologia, 2019, 55, 187-188.	0.8	12
75	Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Research, 2019, 5, 00036-2018.	2.6	29
76	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clinical Cardiology, 2019, 42, 346-351.	1.8	9
77	Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Caseâ€"Control Study With Follow-Up. Archivos De Bronconeumologia, 2019, 55, 312-318.	0.8	4
78	Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients. BMC Pulmonary Medicine, 2019, 19, 112.	2.0	28
79	Global lung health: the dangers of mild lung function impairment. The Lancet Global Health, 2019, 7, e542-e543.	6.3	3
80	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	27.0	180
81	Precision medicine in obstructive sleep apnoea. Lancet Respiratory Medicine,the, 2019, 7, 456-464.	10.7	91
82	Smoking Impairs the Immunomodulatory Capacity of Lung-Resident Mesenchymal Stem Cells in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 575-583.	2.9	13
83	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. European Respiratory Journal, 2019, 53, 1900217.	6.7	25
84	Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. European Respiratory Journal, 2019, 53, 1802058.	6.7	177
85	Physical Activity Is Associated with Attenuated Disease Progression in Chronic Obstructive Pulmonary Disease. Medicine and Science in Sports and Exercise, 2019, 51, 833-840.	0.4	35
86	Heterogeneity and Complexity in Bronchiectasis: A Pending Challenge. Archivos De Bronconeumologia, 2019, 55, 187-188.	0.8	2
87	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
88	Lecciones de una vida: Conferencia Manuel Tapia 2018. Archivos De Bronconeumologia, 2019, 55, 177-180.	0.8	0
89	Arterial Vascular Pruning, Right Ventricular Size, and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. A Longitudinal Observational Study. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 454-461.	5.6	73
90	Lung function trajectories in health and disease. Lancet Respiratory Medicine,the, 2019, 7, 358-364.	10.7	213

#	Article	IF	Citations
91	Chronic obstructive pulmonary disease at the beginning of the XXI Century. Journal of Thoracic Disease, 2019, 11, E210-E213.	1.4	1
92	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	3.2	11
93	Proyecto de biomarcadores y perfiles clÃnicos personalizados en la enfermedad pulmonar obstructiva crÃ³nica (proyecto BIOMEPOC). Archivos De Bronconeumologia, 2019, 55, 93-99.	0.8	18
94	Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis. Respiratory Research, 2019, 20, 5.	3.6	9
95	The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study. Journal of Epidemiology, 2019, 29, 315-324.	2.4	27
96	From systems biology to P4 medicine: applications in respiratory medicine. European Respiratory Review, 2018, 27, 170110.	7.1	35
97	COPD beyond smoking: new paradigm, novel opportunities. Lancet Respiratory Medicine,the, 2018, 6, 324-326.	10.7	47
98	Pharmacological treatment of COPD: the devil is always in the detail. European Respiratory Journal, 2018, 51, 1800263.	6.7	16
99	The disease model: implications for clinical practice. European Respiratory Journal, 2018, 51, 1800188.	6.7	9
100	COPD: time to improve its taxonomy?. ERJ Open Research, 2018, 4, 00132-2017.	2.6	84
101	Filling the gaps in COPD: the TRIBUTE study. Lancet, The, 2018, 391, 1004-1006.	13.7	6
102	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. European Respiratory Journal, 2018, 51, 1702146.	6.7	60
103	Hospitalizations due to exacerbations of COPD: A big data perspective. Respiratory Medicine, 2018, 145, 219-225.	2.9	21
104	Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. European Respiratory Journal, 2018, 51, 1701457.	6.7	39
105	Hepatopulmonary Disorders: Gas Exchange and Vascular Manifestations in Chronic Liver Disease. , 2018, 8, 711-729.		15
106	The Changing Landscape of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 978-981.	5.6	5
107	Cardiovascular Disease Does Not Predict Exacerbation Rate or Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 400-403.	5.6	9
108	Spirometrically Confirmed Chronic Obstructive Pulmonary Disease Worsens Long-Term Prognosis after Percutaneous Coronary Intervention. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 824-826.	5.6	9

#	Article	IF	Citations
109	After asthma: redefining airways diseases. Lancet, The, 2018, 391, 350-400.	13.7	744
110	Pulmonary function predicts mortality and hospitalizations in outpatients with heart failure and preserved ejection fraction. Respiratory Medicine, 2018, 134, 124-129.	2.9	9
111	Do we really need a new classification of airway diseases?. Lancet Respiratory Medicine,the, 2018, 6, 891-893.	10.7	5
112	Expert Panel Discusses the Importance of Systems Medicine. Systems Medicine (New Rochelle, N Y), 2018, 1, 3-8.	1.1	1
113	Treatable traits in bronchiectasis. European Respiratory Journal, 2018, 52, 1801269.	6.7	84
114	Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal, 2018, 52, 1801219.	6.7	166
115	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. Human Molecular Genetics, 2018, 27, 3801-3812.	2.9	32
116	Characterization, localization and comparison of c-Kit+ lung cells in never smokers and smokers with and without COPD. BMC Pulmonary Medicine, 2018, 18, 123.	2.0	6
117	The dyspnoeaâ€"inactivity vicious circle in COPD: development and external validation of a conceptual model. European Respiratory Journal, 2018, 52, 1800079.	6.7	102
118	Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study. ERJ Open Research, 2018, 4, 00022-2018.	2.6	19
119	Precision medicine in COPD exacerbations. Lancet Respiratory Medicine,the, 2018, 6, 657-659.	10.7	23
120	How to Define Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 973-973.	5.6	6
121	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	5.6	111
122	Comparative analysis of COPD associated with tobacco smoking, biomass smoke exposure or both. Respiratory Research, 2018, 19, 13.	3.6	43
123	Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Respiratory Medicine, 2018, 141, 14-19.	2.9	12
124	Estudio de la validez de las versiones en catalÃ¡n, gallego y vasco del cuestionario COPD assessment test y equivalencia con la versiÃ³n en castellano. Archivos De Bronconeumologia, 2017, 53, 311-317.	0.8	3
125	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	2.3	299
126	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 2017, 49, 1700214.	6.7	536

#	Article	IF	Citations
127	Predicting the future from the past. European Respiratory Journal, 2017, 49, 1601854.	6.7	3
128	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	5.6	2,393
129	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.8	173
130	Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. Thorax, 2017, 72, 117-121.	5.6	53
131	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 35-46.	2.9	55
132	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	6.7	194
133	The Intersection of Aging Biology and the Pathobiology of Lung Diseases: A Joint NHLBI/NIA Workshop. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1492-1500.	3.6	55
134	Validity Study of Catalan, Galician and Basque Language Versions of the COPD Assessment Test and Equivalence With the Spanish Version. Archivos De Bronconeumologia, 2017, 53, 311-317.	0.8	1
135	Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. Thorax, 2017, 72, 998-1006.	5.6	65
136	Predicting the future from the past: volatile markers for respiratory infections. European Respiratory Journal, 2017, 49, 1750264.	6.7	1
137	Informe 2017 de la Iniciativa Global para el DiagnÃ³stico, Tratamiento y PrevenciÃ³n de la Enfermedad Pulmonar Obstructiva CrÃ³nica: Resumen Ejecutivo de GOLD. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.8	312
138	Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 428-436.	7.3	13
139	Multi-level differential network analysis of COPD exacerbations. European Respiratory Journal, 2017, 50, 1700075.	6.7	38
140	Precision medicine in airway diseases: moving to clinical practice. European Respiratory Journal, 2017, 50, 1701655.	6.7	151
141	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet, The, 2017, 390, 980-987.	13.7	78
142	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	6.7	64
143	Towards a global initiative for fibrosis treatment (GIFT). ERJ Open Research, 2017, 3, 00106-2017.	2.6	5
144	Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2017, 18, 1097.e11-1097.e24.	2.5	38

#	Article	IF	Citations
145	Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respiratory Medicine,the, 2017, 5, 935-945.	10.7	235
146	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. European Respiratory Journal, 2017, 50, 1700671.	6.7	69
147	Maximal bronchodilation: a therapeutic target in COPD?. Lancet Respiratory Medicine,the, 2017, 5, 540-542.	10.7	2
148	Sex-Based Genetic Association Study Identifies CELSR1 as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 332-341.	2.9	28
149	COPD: algorithms and clinical management. European Respiratory Journal, 2017, 50, 1701733.	6.7	3
150	Natural history of COPD: gaps and opportunities. ERJ Open Research, 2017, 3, 00117-2017.	2.6	40
151	Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. International Journal of COPD, 2017, Volume 12, 2189-2196.	2.3	43
152	The EASI model: A first integrative computational approximation to the natural history of COPD. PLoS ONE, 2017, 12, e0185502.	2.5	4
153	Inspiratory capacityâ€toâ€total lung capacity ratio and dyspnoea predict exercise capacity decline in <scp>COPD</scp>. Respirology, 2016, 21, 476-482.	2.3	16
154	Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine. Annals of the American Thoracic Society, 2016, 13, S466-S470.	3.2	20
155	Usefulness of Bronchoscopic Probe-Based Confocal Laser Endomicroscopy in the Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia. Respiration, 2016, 92, 40-47.	2.6	16
156	Ausencia de correlaciÃ³n entre marcadores de inflamaciÃ³n pulmonar y sistÃ©mica en pacientes con enfermedad pulmonar obstructiva crÃ³nica: un anÃ¡lisis bi-compartimental simultÃ¡neo. Archivos De Bronconeumologia, 2016, 52, 361-367.	0.8	15
157	Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. European Respiratory Journal, 2016, 47, 1299-1303.	6.7	40
158	Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD. Chest, 2016, 150, 123-130.	0.8	50
159	Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 669-676.	1.6	8
160	The inflammasome pathway in stable COPD and acute exacerbations. ERJ Open Research, 2016, 2, 00002-2016.	2.6	47
161	Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1319-1336.	5.6	169
162	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respiratory Medicine, 2016, 119, 87-95.	2.9	29

#	Article	IF	Citations
163	Biomarkers, the control panel and personalized <scp>COPD</scp> medicine. Respirology, 2016, 21, 24-33.	2.3	42
164	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 541-549.	5.6	73
165	Lack of Correlation Between Pulmonary and Systemic Inflammation Markers in Patients with Chronic Obstructive Pulmonary Disease: A Simultaneous, Two-Compartmental Analysis. Archivos De Bronconeumologia, 2016, 52, 361-367.	0.8	14
166	Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 48-57.	5.6	52
167	A comparison of COPD patients with and without ACOS in the ECLIPSE study. European Respiratory Journal, 2016, 47, 1559-1562.	6.7	35
168	Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials Communications, 2016, 2, 91-96.	1.1	12
169	Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. European Respiratory Journal, 2016, 47, 1365-1373.	6.7	64
170	Simple versus complex COPD: implications for health-care management. Lancet Respiratory Medicine,the, 2016, 4, e6-e7.	10.7	2
171	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	6.7	746
172	Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1242-1253.	5.6	99
173	Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 427-437.	5.6	139
174	COPD. , 2016, , 751-766.e7.		2
175	Haemophilus influenzae induces steroid-resistant inflammatory responses in COPD. BMC Pulmonary Medicine, 2015, 15, 157.	2.0	17
176	Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. PLoS ONE, 2015, 10, e0135199.	2.5	62
177	Ventilation/Perfusion Distribution Abnormalities In Morbidly Obese Subjects Before and After Bariatric Surgery. Chest, 2015, 147, 1127-1134.	0.8	44
178	Drug development for airway diseases: looking forward. Nature Reviews Drug Discovery, 2015, 14, 367-368.	46.4	18
179	Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 523-525.	5.6	338
180	B Cellâ€"Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 695-705.	5.6	89

#	Article	IF	Citations
181	Chronic obstructive pulmonary disease: The golden decade. Implications for the diagnosis, prevention and treatment of chronic obstructive pulmonary disease. Medicina ClÃnica (English Edition), 2015, 144, 507-513.	0.2	1
182	Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 391-401.	5.6	61
183	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Annals of the American Thoracic Society, 2015, 12, 303-312.	3.2	126
184	Benefits of physical activity on COPD hospitalisation depend on intensity. European Respiratory Journal, 2015, 46, 1281-1289.	6.7	67
185	Molecular and clinical diseasome of comorbidities in exacerbated COPD patients. European Respiratory Journal, 2015, 46, 1001-1010.	6.7	32
186	The asthmaâ€"COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. Lancet Respiratory Medicine,the, 2015, 3, 719-728.	10.7	142
187	Inhaled steroids in COPD: Reasons for a debate. Revista Portuguesa De Pneumologia, 2015, 21, 175-177.	0.7	4
188	Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of Emphysema and the RAGE Axis in the Lung. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 785-792.	5.6	82
189	Clinical and prognostic heterogeneity of C and D GOLD groups. European Respiratory Journal, 2015, 46, 250-254.	6.7	11
190	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 111-122.	27.0	974
191	Heterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposal. Lancet Respiratory Medicine,the, 2015, 3, 729-734.	10.7	46
192	IREB2 and GALC Are Associated with Pulmonary Artery Enlargement in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 365-376.	2.9	26
193	Assessment of health status and program performance in patients on long-term oxygen therapy. Respiratory Medicine, 2015, 109, 500-509.	2.9	18
194	Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet, The, 2015, 385, 1789-1798.	13.7	209
195	Characterisation and prognosis of undiagnosed chronic obstructive pulmonary disease patients at their first hospitalisation. BMC Pulmonary Medicine, 2015, 15, 4.	2.0	20
196	One-year change in health status and subsequent outcomes in COPD. Thorax, 2015, 70, 420-425.	5.6	50
197	Hospitalized Exacerbations of COPD. Chest, 2015, 147, 999-1007.	0.8	269
198	Salmeterol/fluticasone combination instead of indacaterol or vice-versa?. European Respiratory Journal, 2015, 45, 1187-1188.	6.7	1

#	Article	IF	Citations
199	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	5.6	166
200	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	6.7	138
201	Lung-Function Trajectories and Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 1574-1575.	27.0	23
202	Implementing systems medicine within healthcare. Genome Medicine, 2015, 7, 102.	8.2	13
203	Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. Cancer Immunology, Immunotherapy, 2015, 64, 1261-1270.	4.2	27
204	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146.	2.9	77
205	Network analysis: a way forward for understanding COPD multimorbidity. European Respiratory Journal, 2015, 46, 591-592.	6.7	12
206	Continuous fat-free mass decline in COPD: fact or fiction?. European Respiratory Journal, 2015, 46, 1496-1498.	6.7	12
207	Systemic Inflammatory Response to Smoking in Chronic Obstructive Pulmonary Disease: Evidence of a Gender Effect. PLoS ONE, 2014, 9, e97491.	2.5	40
208	The Systemic Inflammome of Severe Obesity before and after Bariatric Surgery. PLoS ONE, 2014, 9, e107859.	2.5	42
209	S49 Telomere Attrition In Circulating White Blood Cells In Copd Relates To Lung Function And Outcomes. Thorax, 2014, 69, A28-A28.	5.6	0
210	Fibrinogen and COPD: Now what?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 1-3.	0.7	16
211	Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 166-184.	0.7	23
212	Network medicine, multimorbidity and the lung in the elderly. European Respiratory Journal, 2014, 44, 775-788.	6.7	63
213	A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. BMC Systems Biology, 2014, 8, S8.	3.0	24
214	Network Analysis in the Investigation of Chronic Respiratory Diseases. From Basics to Application. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 981-988.	5.6	42
215	Air pollution and biomarkers of systemic inflammation and tissue repair in COPD patients. European Respiratory Journal, 2014, 44, 603-613.	6.7	94
216	Inhaled corticosteroids and systemic inflammatory response in communityâ€acquired pneumonia: A prospective clinical study. Respirology, 2014, 19, 929-935.	2.3	20

#	Article	IF	Citations
217	Prevalence of and risk factors for pulmonary abnormalities in <scp>HIV</scp>â€infected patients treated with antiretroviral therapy. HIV Medicine, 2014, 15, 321-329.	2.2	64
218	Common Genetic Variants Associated with Resting Oxygenation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 678-687.	2.9	19
219	Network medicine analysis of COPD multimorbidities. Respiratory Research, 2014, 15, 111.	3.6	48
220	S51 Circulating Desmosine Relates To Cardiovascular Comorbidity, Coronary Artery Calcification Score (cacs), Systemic Inflammation And Mortality In Patients With Copd. Thorax, 2014, 69, A28-A29.	5.6	1
221	An inter-rater reliability study of the prescribing indicated medications quality indicators of the Assessing Care Of Vulnerable Elders (ACOVE) 3 criteria as a potentially inappropriate prescribing tool. Archives of Gerontology and Geriatrics, 2014, 58, 460-464.	3.0	11
222	Biomarkers in COPD. Clinics in Chest Medicine, 2014, 35, 131-141.	2.1	48
223	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014, 69, 718-723.	5.6	151
224	Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?. Thorax, 2014, 69, 72-79.	5.6	65
225	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respiratory Medicine, 2014, 108, 1647-1654.	2.9	22
226	Inhaled steroids in COPD: when should they be used?. Lancet Respiratory Medicine,the, 2014, 2, 869-871.	10.7	26
227	Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary Disease. Respiratory Medicine, 2014, 108, 1608-1614.	2.9	55
228	A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. European Respiratory Journal, 2014, 43, 763-772.	6.7	52
229	Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. European Respiratory Journal, 2014, 44, 1156-1165.	6.7	60
230	Statins as adjunct therapy in COPD: how do we cope after STATCOPE?. Thorax, 2014, 69, 891-894.	5.6	24
231	Structureâ€"function relationship in COPD revisited: an in vivo microscopy view. Thorax, 2014, 69, 724-730.	5.6	9
232	The path to personalised medicine in COPD. Thorax, 2014, 69, 857-864.	5.6	158
233	Lung Function Abnormalities are Highly Frequent in Patients with Heart Failure and Preserved Ejection Fraction. Heart Lung and Circulation, 2014, 23, 273-279.	0.4	35
234	Quantitative Computed Tomography Measures of Pectoralis Muscle Area and Disease Severity in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study. Annals of the American Thoracic Society, 2014, 11, 326-334.	3.2	168

#	Article	IF	Citations
235	Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323.	6.7	154
236	Lessons from ECLIPSE: a review of COPD biomarkers. Thorax, 2014, 69, 666-672.	5.6	125
237	Hospital admissions and exercise capacity decline in patients with COPD. European Respiratory Journal, 2014, 43, 1018-1027.	6.7	40
238	Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respiratory Medicine, 2014, 108, 1153-1162.	2.9	99
239	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1022-1030.	5.6	130
240	Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management. Journal of Translational Medicine, 2014, 12, S3.	4.4	34
241	A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases. Current Pharmaceutical Design, 2014, 20, 5945-5956.	1.9	32
242	A randomised trial of fluticasone furoate/vilanterol (50/25ÂÎ¼g; 100/25ÂÎ¼g) on lung function in COPD. Respiratory Medicine, 2013, 107, 560-569.	2.9	83
243	Systemic Soluble Receptor for Advanced Glycation Endproducts Is a Biomarker of Emphysema and Associated with AGER Genetic Variants in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 948-957.	5.6	138
244	Cardiovascular Comorbidity in COPD. Chest, 2013, 144, 1163-1178.	0.8	278
245	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respiratory Medicine, 2013, 107, 1376-1384.	2.9	328
246	Pathophysiology of muscle dysfunction in COPD. Journal of Applied Physiology, 2013, 114, 1222-1234.	2.5	164
247	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 347-365.	5.6	7,792
248	Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach. Respiratory Medicine, 2013, 107, 1817-1821.	2.9	87
249	Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. Respiratory Medicine, 2013, 107, 1895-1903.	2.9	22
250	Integrating real-life studies in the global therapeutic research framework. Lancet Respiratory Medicine,the, 2013, 1, e29-e30.	10.7	102
251	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine,the, 2013, 1, 129-136.	10.7	224
252	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386.	5.6	257

#	Article	IF	Citations
253	FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. European Respiratory Journal, 2013, 42, 1391-1401.	6.7	87
254	Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. Annals of Nutrition and Metabolism, 2013, 63, 239-247.	1.9	46
255	Lungs, Bone Marrow, and Adipose Tissue. A Network Approach to the Pathobiology of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1396-1406.	5.6	32
256	What Is Chronic Obstructive Pulmonary Disease Anyway?. Continua, Categories, Cut Points, and Moving beyond Spirometry. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1036-1037.	5.6	19
257	Reply: Look at the Moon, Not Just at the Finger Indicating the Moon. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 329-330.	5.6	0
258	The COPD control panel: towards personalised medicine in COPD. Thorax, 2013, 68, 687-690.	5.6	96
259	Phenotypes and Disease Characterization in Chronic Obstructive Pulmonary Disease. Toward the Extinction of Phenotypes?. Annals of the American Thoracic Society, 2013, 10, S125-S130.	3.2	42
260	HLA Distribution in COPD Patients. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 138-146.	1.6	15
261	Immune response in chronic obstructive pulmonary disease. Expert Review of Clinical Immunology, 2013, 9, 821-833.	3.0	39
262	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. European Respiratory Journal, 2013, 42, 636-646.	6.7	164
263	Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis. Journal of Thoracic Oncology, 2013, 8, e34.	1.1	3
264	Dayâ€"night variations in endothelial dysfunction markers and haemostatic factors in sleep apnoea. European Respiratory Journal, 2012, 39, 913-918.	6.7	19
265	COPD and the Solar System. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 117-119.	5.6	29
266	Update in Chronic Obstructive Pulmonary Disease 2011. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1171-1176.	5.6	22
267	Systemic Inflammation and Comorbidities in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2012, 9, 43-46.	3.5	58
268	Cured meat consumption increases risk of readmission in COPD patients. European Respiratory Journal, 2012, 40, 555-560.	6.7	36
269	Abnormal Lung Aging in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 306-313.	5.6	220
270	Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal, 2012, 40, 830-836.	6.7	168

#	Article	IF	Citations
271	Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension. JAMA - Journal of the American Medical Association, 2012, 307, 2169-76.	7.4	595
272	Systemic Steroid Exposure Is Associated with Differential Methylation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1248-1255.	5.6	64
273	Monitoring Breathing Rate at Home Allows Early Identification of COPD Exacerbations. Chest, 2012, 142, 1524-1529.	0.8	93
274	Chronic Obstructive Pulmonary Disease Phenotypes: Current Rather than Future Perspectives. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 590-590.	5.6	1
275	Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1238-1247.	5.6	117
276	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax, 2012, 67, 701-708.	5.6	160
277	The influence of obesity and obstructive sleep apnea on metabolic hormones. Sleep and Breathing, 2012, 16, 649-656.	1.7	59
278	The GOLD Initiative 2011: A Change of Paradigm?. Archivos De Bronconeumologia, 2012, 48, 286-289.	0.8	8
279	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297.	2.5	193
280	Effect of Bronchial Colonisation on Airway and Systemic Inflammation in Stable COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 121-130.	1.6	56
281	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1065-1072.	5.6	353
282	Iniciativa GOLD 2011. Â¿Cambio de paradigma?. Archivos De Bronconeumologia, 2012, 48, 286-289.	0.8	17
283	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Human Molecular Genetics, 2012, 21, 947-957.	2.9	216
284	An investigation of the resolution of inflammation (catabasis) in COPD. Respiratory Research, 2012, 13, 101.	3.6	19
285	Is The CAT Questionnaire Sensitive To Changes In Health Status In Patients With Severe COPD Exacerbations?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 492-498.	1.6	70
286	Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Human Molecular Genetics, 2012, 21, 3073-3082.	2.9	269
287	Site of Mitochondrial Reactive Oxygen Species Production in Skeletal Muscle of Chronic Obstructive Pulmonary Disease and Its Relationship with Exercise Oxidative Stress. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 358-362.	2.9	47
288	Variable DNA Methylation Is Associated with Chronic Obstructive Pulmonary Disease and Lung Function. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 373-381.	5.6	196

#	Article	IF	Citations
289	Impaired circadian variation of platelet activity in patients with sleep apnea. Sleep and Breathing, 2012, 16, 355-360.	1.7	22
290	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 2012, 7, e37483.	2.5	633
291	Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study. PLoS ONE, 2012, 7, e42156.	2.5	95
292	Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Medicine, 2011, 3, 43.	8.2	181
293	Current Controversies and Future Perspectives in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 507-513.	5.6	98
294	P4 Medicine: the Future Around the Corner. Archivos De Bronconeumologia, 2011, 47, 35-40.	0.8	32
295	Medicina P4: el futuro a la vuelta de la esquina. Archivos De Bronconeumologia, 2011, 47, 35-40.	0.8	44
296	Mecanismos moleculares de inflamaciÃ³n durante las agudizaciones de la enfermedad pulmonar obstructiva crÃ³nica. Archivos De Bronconeumologia, 2011, 47, 176-183.	0.8	57
297	Non-synonymous polymorphism in the neuropeptide S precursor gene and sleep apnea. Sleep and Breathing, 2011, 15, 403-408.	1.7	4
298	COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respiratory Research, 2011, 12, 146.	3.6	134
299	Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research, 2011, 12, 55.	3.6	70
300	Anti-Tissue Antibodies Are Related to Lung Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1025-1031.	5.6	96
301	Is Autoimmunity Really Related to the Pathogenesis of COPD?. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1213-1213.	5.6	12
302	Night-time symptoms: a forgotten dimension of COPD. European Respiratory Review, 2011, 20, 183-194.	7.1	182
303	The CIBERES Pulmonary Biobank Consortium: an opportunity for cooperative international respiratory research. European Respiratory Journal, 2011, 37, 204-206.	6.7	9
304	Genome-wide association study of smoking behaviours in patients with COPD. Thorax, 2011, 66, 894-902.	5.6	95
305	Candidate genes for COPD in two large data sets. European Respiratory Journal, 2011, 37, 255-263.	6.7	44
306	Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines. Thorax, 2011, 66, 745-747.	5.6	31

#	Article	IF	Citations
307	Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. European Respiratory Journal, 2011, 38, 749-751.	6.7	40
308	Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. Thorax, 2011, 66, 903-909.	5.6	26
309	Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax, 2011, 66, 430-437.	5.6	271
310	P255 ATTAIN: twice-daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease. Thorax, 2011, 66, A171-A172.	5.6	1
311	Addressing the Complexity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1129-1137.	5.6	166
312	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192.	27.0	811
313	Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 121-135.	1.6	43
314	Effects of exercise on mitochondrial DNA content in skeletal muscle of patients with COPD. Thorax, 2011, 66, 121-127.	5.6	61
315	Î±; 1 -Antitrypsin Protease Inhibitor MZ Heterozygosity Is Associated With Airflow Obstruction in Two Large Cohorts. Chest, 2010, 138, 1125-1132.	0.8	77
316	Abnormal Levels of Circulating Endothelial Progenitor Cells During Exacerbations of COPD. Lung, 2010, 188, 331-338.	3.3	41
317	Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, 11, 122.	3.6	952
318	Low Erythropoietin Plasma Levels during Exacerbations of COPD. Respiration, 2010, 80, 190-197.	2.6	21
319	Variability and effects of bronchial colonisation in patients with moderate COPD. European Respiratory Journal, 2010, 35, 295-302.	6.7	82
320	High Prevalence of Undiagnosed Airflow Limitation in Patients With Cardiovascular Disease. Chest, 2010, 137, 333-340.	0.8	81
321	S113 The effect of small airways disease and emphysema on the association between smoking and lung function, and bronchodilator response. Thorax, 2010, 65, A52-A52.	5.6	0
322	What the Journal Would Like to Publish on Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1-2.	5.6	9
323	Update in Chronic Obstructive Pulmonary Disease 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 655-660.	5.6	23
324	Multistudy Fine Mapping of Chromosome 2q Identifies XRCC5 as a Chronic Obstructive Pulmonary Disease Susceptibility Gene. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 605-613.	5.6	29

#	Article	IF	Citations
325	Clinical Audit of Patients Admitted to Hospital in Spain due to Exacerbation of COPD (AUDIPOC Study): Method and Organisation. Archivos De Bronconeumologia, 2010, 46, 349-357.	0.8	23
326	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2010, 363, 1128-1138.	27.0	2,359
327	Telomere shortening in sleep apnea syndrome. Respiratory Medicine, 2010, 104, 1225-1229.	2.9	61
328	Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604.	5.6	898
329	Enfermedad pulmonar obstructiva crÃ³nica: Concepto, factores etiolÃ³gicos y patogenia. , 2010, , 171-177.		0
330	Nontypeable Haemophilus influenzae Clearance by Alveolar Macrophages Is Impaired by Exposure to Cigarette Smoke. Infection and Immunity, 2009, 77, 4232-4242.	2.2	115
331	Increased Plasma Levels of Asymmetric Dimethylarginine and Soluble CD40 Ligand in Patients with Sleep Apnea. Respiration, 2009, 77, 85-90.	2.6	32
332	Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax, 2009, 64, 424-429.	5.6	131
333	The Natural History of Chronic Airflow Obstruction Revisited. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 3-10.	5.6	516
334	Abnormal Transition Pore Kinetics and Cytochrome C Release in Muscle Mitochondria of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 746-750.	2.9	40
335	Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients. European Respiratory Journal, 2009, 33, 1045-1052.	6.7	150
336	A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci. PLoS Genetics, 2009, 5, e1000421.	3.5	656
337	A controlled trial of noninvasive ventilation for chronic obstructive pulmonary disease exacerbations. Journal of Critical Care, 2009, 24, 473.e7-473.e14.	2.2	43
338	CTLA4 gene polymorphisms are associated with chronic bronchitis. European Respiratory Journal, 2009, 34, 598-604.	6.7	27
339	Prediction of risk of COPD exacerbations by the BODE index. Respiratory Medicine, 2009, 103, 373-378.	2.9	116
340	Characteristics of patients admitted for the first time for COPD exacerbation. Respiratory Medicine, 2009, 103, 1293-1302.	2.9	54
341	Immunologic Aspects of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2009, 360, 2445-2454.	27.0	684
342	Systemic Manifestations. , 2009, , 569-578.		0

#	Article	IF	Citations
343	Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax, 2009, 64, 581-586.	5.6	154
344	Physical Activity and Clinical and Functional Status in COPD. Chest, 2009, 136, 62-70.	0.8	142
345	Investigating the Natural History of Lung Function. Chest, 2009, 135, 1330-1341.	0.8	31
346	Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease. Journal of Clinical Investigation, 2009, 119, 636-649.	8.2	65
347	COPD as a Systemic Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 133-138.	1.6	204
348	Endothelial Function and Circulating Endothelial Progenitor Cells in Patients with Sleep Apnea Syndrome. Respiration, 2008, 76, 28-32.	2.6	73
349	Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. European Respiratory Journal, 2008, 31, 555-562.	6.7	166
350	Chronic Obstructive Pulmonary Disease: Beyond the Forced Expiratory Manoeuvre. Respiration, 2008, 75, 136-137.	2.6	4
351	Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 500-505.	5.6	268
352	Fluticasone propionate reduces bacterial airway epithelial invasion. European Respiratory Journal, 2008, 32, 1283-1288.	6.7	26
353	Lipopolysaccharide-binding protein and CD14 are increased in the bronchoalveolar lavage fluid of smokers. European Respiratory Journal, 2008, 33, 273-281.	6.7	40
354	Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax, 2008, 63, 946-950.	5.6	141
355	Physical Activity and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 675-676.	5.6	11
356	Reflections on TORCH: Potential Mechanisms for the Survival Benefit of Salmeterol/Fluticasone Propionate in COPD Patients. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 369-375.	1.6	8
357	Systemic Effects of COPD: Just the Tip of the Iceberg. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 205-206.	1.6	4
358	Daytime sleepiness and polysomnographic variables in sleep apnoea patients. European Respiratory Journal, 2007, 30, 110-113.	6.7	185
359	Effect of Continuous Positive Airway Pressure on the Risk of Road Accidents in Sleep Apnea Patients. Respiration, 2007, 74, 44-49.	2.6	48
360	Prostaglandin D synthase (Î² trace) levels in sleep apnea patients with and without sleepiness. Sleep Medicine, 2007, 8, 509-511.	1.6	38

#	Article	IF	Citations
361	Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should). Proceedings of the American Thoracic Society, 2007, 4, 522-525.	3.5	203
362	Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness. Sleep and Breathing, 2007, 11, 177-185.	1.7	85
363	Mortality in COPD: role of comorbidities. European Respiratory Journal, 2006, 28, 1245-1257.	6.7	864
364	Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respiratory Research, 2006, 7, 64.	3.6	69
365	Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clinical and Experimental Immunology, 2006, 145, 474-479.	2.6	103
366	Thomas A. Neff Lecture. Chronic Obstructive Pulmonary Disease: A Systemic Disease. Proceedings of the American Thoracic Society, 2006, 3, 478-481.	3.5	53
367	Telomere shortening in smokers with and without COPD. European Respiratory Journal, 2006, 27, 525-528.	6.7	286
368	Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. European Respiratory Journal, 2006, 27, 756-760.	6.7	179
369	The potential impact of anaemia of chronic disease in COPD. European Respiratory Journal, 2006, 27, 390-396.	6.7	138
370	Outcomes and markers in the assessment of chronic obstructive pulmonary disease. European Respiratory Journal, 2006, 27, 822-832.	6.7	212
371	Tratamiento hospitalario de los episodios de agudizaciÃ³n de la EPOC. Una revisiÃ³n basada en la evidencia. Archivos De Bronconeumologia, 2005, 41, 220-229.	0.8	14
372	Blunted ÂÂ T-lymphocyte response in chronic obstructive pulmonary disease. European Respiratory Journal, 2005, 25, 441-446.	6.7	44
373	Neuropeptide Y and Leptin in Patients with Obstructive Sleep Apnea Syndrome. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 183-187.	5.6	122
374	Systemic Effects of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2005, 2, 367-370.	3.5	234
375	Decreased macrophage release of TGF-Â and TIMP-1 in chronic obstructive pulmonary disease. European Respiratory Journal, 2005, 26, 60-66.	6.7	51
376	Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. European Respiratory Journal, 2005, 25, 647-652.	6.7	86
377	Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax, 2005, 60, 293-300.	5.6	308
378	Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet, The, 2005, 365, 1046-1053.	13.7	4,014

#	Article	IF	Citations
379	COPD, a multicomponent disease: implications for management. Respiratory Medicine, 2005, 99, 670-682.	2.9	173
380	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respiratory Medicine, 2005, 99, 1546-1554.	2.9	59
381	Effects of obesity upon genioglossus structure and function in obstructive sleep apnoea. European Respiratory Journal, 2004, 23, 425-429.	6.7	81
382	Decreased Plasma Levels of Orexin-A in Sleep Apnea. Respiration, 2004, 71, 575-579.	2.6	63
383	Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. American Journal of Medicine, 2004, 117, 118-121.	1.5	119
384	Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal, 2004, 23, 932-946.	6.7	3,804
385	Expression of Adhesion Molecules During Apoptosis of Circulating Neutrophils in COPD. Chest, 2004, 125, 1837-1842.	0.8	41
386	Nitric oxide synthase type I (nNOS), vascular endothelial growth factor (VEGF) and myoglobin-like expression in skeletal muscle of Antarctic icefishes (Notothenioidei: Channichthyidae). Polar Biology, 2003, 26, 458-462.	1.2	16
387	Long-term (72 hours) preservation of rat lungs. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 907-912.	0.8	2
388	Differential Response of Lymphocytes and Neutrophils to High Intensity Physical Activity and to Vitamin C Diet Supplementation. Free Radical Research, 2003, 37, 931-938.	3.3	44
389	Skeletal muscle changes in patients with obstructive sleep apnoea syndrome. Respiratory Medicine, 2003, 97, 804-810.	2.9	47
390	Systemic effects of chronic obstructive pulmonary disease. European Respiratory Journal, 2003, 21, 347-360.	6.7	755
391	Hypothesis: Does COPD have an autoimmune component?. Thorax, 2003, 58, 832-834.	5.6	239
392	Skeletal Muscle Apoptosis and Weight Loss in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 485-489.	5.6	302
393	Weight Loss in Chronic Obstructive Pulmonary Disease. Mechanisms and Implications. Pulmonary Pharmacology and Therapeutics, 2002, 15, 425-432.	2.6	19
394	Plasminogen activator inhibitor-1 (PAI-1) polymorphisms in patients with obstructive sleep apnoea. Respiratory Medicine, 2002, 96, 193-196.	2.9	14
395	Supported discharge shortens hospital stay in patients hospitalized because of an exacerbation of COPD. European Respiratory Journal, 2001, 17, 1138-1142.	6.7	55
396	Angiotensin converting enzyme in patients with sleep apnoea syndrome: plasma activity and gene polymorphisms. European Respiratory Journal, 2001, 17, 728-732.	6.7	82

#	Article	IF	Citations
397	Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax, 2001, 56, 432-437.	5.6	192
398	Long-term effects of CPAP on daytime functioning in patients with sleep apnoea syndrome. European Respiratory Journal, 2000, 15, 676-681.	6.7	138
399	Management of chronic obstructive pulmonary disease: are we going anywhere?. European Respiratory Journal, 2000, 16, 1035-1036.	6.7	19
400	Changes induced by oxygen in rat liver proteins identified by high-resolution two-dimensional gel electrophoresis. FEBS Journal, 2000, 267, 5580-5584.	0.2	6
401	Abnormal lipid peroxidation in patients with sleep apnoea. European Respiratory Journal, 2000, 16, 644.	6.7	220
402	Regulation of iNOS expression and glutathione levels in rat liver by oxygen tension. FEBS Letters, 2000, 476, 253-257.	2.8	30
403	The measurement of exhaled carbon monoxide is influenced by airflow obstruction. European Respiratory Journal, 2000, 15, 177.	6.7	0
404	Lack of effects of moderate-high altitude upon lung function in healthy middle-aged volunteers. Respiratory Medicine, 1999, 93, 739-743.	2.9	9
405	Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal, 1999, 14, 523.	6.7	110
406	Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal, 1999, 14, 934.	6.7	53
407	Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. European Journal of Clinical Pharmacology, 1998, 54, 203-208.	1.9	20
408	Does the number of hypopnoeas influence therapy in patients with obstructive sleep apnoea?. Respiratory Medicine, 1998, 92, 1028-1031.	2.9	2
409	Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction Towards an understanding of factors influencing clinical practice. European Heart Journal, 1998, 19, 74-79.	2.2	48
410	Structure and function relationships of the respiratory muscles. European Respiratory Journal, 1998, 11, 906-911.	6.7	33
411	Effects of N-acetylcysteine on tissue oxygenation in patients with multiple organ failure and evidence of tissue hypoxia. European Respiratory Journal, 1997, 10, 1962-1966.	6.7	27
412	MECHANISMS OF GAS EXCHANGE IMPAIRMENT IN PATIENTS WITH LIVER CIRRHOSIS. Clinics in Chest Medicine, 1996, 17, 49-66.	2.1	77
413	Long-term Effects of Nasal Intermittent Positive-Pressure Ventilation on Pulmonary Function and Sleep Architecture in Patients With Neuromuscular Diseases. Chest, 1996, 110, 1179-1183.	0.8	118
414	Continuous positive airway pressure is effective in treating upper airway oedema. European Respiratory Journal, 1996, 9, 1092-1093.	6.7	9

#	Article	IF	Citations
415	Noninvasive ventilatory support does not facilitate recovery from acute respiratory failure in chronic obstructive pulmonary disease. European Respiratory Journal, 1996, 9, 1240-1245.	6.7	199
416	Apnoea in Duchenne muscular dystrophy.. Thorax, 1995, 50, 1123-1123.	5.6	4
417	Contribution of multiple inert gas elimination technique to pulmonary medicine. 2. Chronic pulmonary diseases: chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.. Thorax, 1994, 49, 924-932.	5.6	44
418	Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. European Respiratory Journal, 1994, 7, 643-650.	6.7	57
419	Sleep-related respiratory disturbances in patients with Duchenne muscular dystrophy. European Respiratory Journal, 1994, 7, 1403-1408.	6.7	127
420	Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up.. Thorax, 1992, 47, 1035-1040.	5.6	62
421	The hepatopulmonary syndrome: new name, old complexities.. Thorax, 1992, 47, 897-902.	5.6	218
422	Mechanisms of Abnormal Gas Exchange in Patients with Pneumonia. Anesthesiology, 1991, 75, 782-789.	2.5	54
423	Hypoxic Pulmonary Vasoconstriction and Gas Exchange During Exercise in Chronic Obstructive Pulmonary Disease. Chest, 1990, 97, 268-275.	0.8	139
424	The lung in patients with cirrhosis. Journal of Hepatology, 1990, 10, 251-257.	3.7	100
425	Pulmonary function and liver disease. Current Opinion in Gastroenterology, 1988, 4, 609-614.	2.3	12
426	Oxyhemoglobin affinity in patients with chronic obstructive pulmonary disease and acute respiratory failure. Critical Care Medicine, 1986, 14, 610-613.	0.9	29
427	Proper Use of Metered Dose Inhalers. Chest, 1985, 88, 159-160.	0.8	6
428	ARDS and Pneumococcal Pneumonia. Chest, 1984, 85, 584.	0.8	4
429	Hypophosphatemia as a cause of failed weaning. Critical Care Medicine, 1984, 12, 142-143.	0.9	74
430	Respiratory Illness and Hypophosphatemia. Chest, 1983, 84, 786.	0.8	3
431	Effect of Bronchial Colonisation on Airway and Systemic Inflammation in Stable COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 0, , 140924102835001.	1.6	0